Splenomegaly Clinical Trial
Official title:
Estimation of Spleen Size With Hand Held Ultrasound
In internal medicine, assessment of spleen size on physical examination is an extremely important part of the overall evaluation of patients with many illnesses. Examination of the spleen is also one of the core competencies that the investigators expect our students and residents to learn as part of their training. Unfortunately, the sensitivity and specificity of examination of the spleen at the bedside is not very good. The investigators wish to determine if handheld ultrasound can accurately assess spleen size. Doing so would make physical examination of the spleen obsolete and transform training objectives for medical students and residents.
The diagnosis of splenomegaly (abnormal enlargement of the spleen) is extremely important in
managing patients with many medical conditions. The ability to recognize an enlarged spleen
in a timely manner can impact patient outcomes. Although the physical exam can be used to
confidently diagnosis massive enlargement of the spleen, evaluating lesser degrees of
splenomegaly at the bedside proves more difficult. In current practice, the gold standard
for diagnosis of splenomegaly is the standard abdominal ultrasound. The prevalence of
splenomegaly in patients with several medical conditions such as blood disorders and
cirrhosis is relatively high. Therefore, the demand for abdominal ultrasound is evergrowing
and similarly the cost of caring for patients with these diseases increases.
Examination of the spleen is one of the core competencies that we expect our students and
residents to learn as part of their training. This physical diagnosis manoeuver is
frequently used to examine residents at the Royal College level and determine their fitness
to practice. Unfortunately, the sensitivity and specificity of examination of the spleen at
the bedside is not very good.
With the introduction of handheld ultrasound (HCU) devices, rapid bedside assessment of a
patient is now possible. The Pocket-sized Vscan Ultrasound device (Vscan) (GE Healthcare,
USA) allows for 2D imaging on a 3.5 inch display and has been shown to have comparable image
quality to standard ultrasound for some applications. The Vscan and other HCU devices have
been used at point of care to evaluate a number of conditions and can greatly impact
treatment decisions in medical patients at the bedside. The ability to recognize
splenomegaly in a timely manner can impact patient outcomes. In addition, the use of this
technology could significantly impact training standards for students and residents.
It remains unclear whether bedside evaluation with the Vscan is able to accurately measure
spleen size. Our study aims to determine the diagnostic accuracy of the Vscan when used by
trained ultrasonographers, in patients with varying degrees of splenomegaly. If we can
reliably show that a trained ultrasonographer can accurately characterize spleen size at the
bedside with a handheld device, the next stage of the study will involve training medical
residents in the use of handheld ultrasound to see if they can also reliably assess spleen
size.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT06345495 -
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
|
Phase 2 | |
Completed |
NCT04430881 -
A National Study in Patients With Unexplained Splenomegaly
|
||
Completed |
NCT01948076 -
Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination
|
N/A | |
Completed |
NCT04716166 -
Incentive Spirometry and Upper Abdominal Laparoscopic Surgery
|
N/A | |
Completed |
NCT01907932 -
Estimation of Spleen by Residents With VScan
|
N/A | |
Recruiting |
NCT03801434 -
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
|
Phase 2 | |
Terminated |
NCT02421354 -
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
|
Phase 2 | |
Recruiting |
NCT05641103 -
PREDIGA 2: Spanish Acronym of "Educational and Diagnostic Project for Gaucher and ASMD"
|
||
Recruiting |
NCT01201655 -
Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
|
N/A | |
Active, not recruiting |
NCT02871219 -
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
|
Phase 2 | |
Completed |
NCT00006148 -
Spleen Size in Peripheral Blood Stem Cell Donors
|
N/A | |
Withdrawn |
NCT02298634 -
Biomarker for Farber Disease (BioFarber)
|
||
Withdrawn |
NCT01331642 -
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
|
||
Withdrawn |
NCT02298699 -
Biomarker for Sly Disease (MPS VII) (BioSly)
|
||
Terminated |
NCT02730884 -
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
|
Phase 2 | |
Terminated |
NCT02463669 -
The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
|